1. Bray F, Ferlay J, Soerjomataram I, et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492
2. Schneider BP, Miller KD (2005) Angiogenesis of Breast Cancer. J Clin Oncol 23:1782–1790. https://doi.org/10.1200/JCO.2005.12.017
3. Fox SB, Generali DG, Harris AL (2007) Breast tumour angiogenesis. Breast Cancer Res 9:216. https://doi.org/10.1186/bcr1796
4. Bear HD, Tang G, Rastogi P, et al (2012) Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer. N Engl J Med 366:310–320. https://doi.org/10.1056/NEJMoa1111097
5. Rugo HS (2012) Inhibiting Angiogenesis in Breast Cancer: The Beginning of the End or the End of the Beginning? J Clin Oncol 30:898–901. https://doi.org/10.1200/JCO.2011.38.5492
6. Maj E, Papiernik D, Wietrzyk J (2016) Antiangiogenic cancer treatment: The great discovery and greater complexity (Review). Int J Oncol 49:1773–1784. https://doi.org/10.3892/ijo.2016.3709
7. Jain RK (2005) Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy. Science (80- ) 307:58–62. https://doi.org/10.1126/science.1104819
8. Perrot-Applanat M, Di Benedetto M (2012) Autocrine functions of VEGF in breast tumor cells. Cell Adh Migr 6:547–553. https://doi.org/10.4161/cam.23332
9. Wolff AC, Hammond MEH, Allison KH, et al (2018) Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Arch Pathol Lab Med 142:1364–1382. https://doi.org/10.5858/arpa.2018-0902-SA
10. Therasse P, Arbuck SG, Eisenhauer EA, et al (2000) New Guidelines to Evaluate the Response to Treatment in Solid Tumors. JNCI J Natl Cancer Inst 92:205–216. https://doi.org/10.1093/jnci/92.3.205
11. Fakhrejahani E, Toi M (2012) Tumor Angiogenesis: Pericytes and Maturation Are Not to Be Ignored. J Oncol 2012:1–10. https://doi.org/10.1155/2012/261750
12. Trinh XB, Tjalma WAA, Vermeulen PB, et al (2009) The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer. Br J Cancer 100:971–978. https://doi.org/10.1038/sj.bjc.6604921
13. Smith IC (2002) Neoadjuvant Chemotherapy in Breast Cancer: Significantly Enhanced Response With Docetaxel. J Clin Oncol 20:1456–1466. https://doi.org/10.1200/JCO.20.6.1456
14. Tong RT, Boucher Y, Kozin S V., et al (2004) Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors. Cancer Res 64:3731–3736. https://doi.org/10.1158/0008-5472.CAN-04-0074
15. Winkler F, Kozin S V., Tong RT, et al (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation. Cancer Cell 6:553–563. https://doi.org/10.1016/j.ccr.2004.10.011
16. El-Gohary YM, Metwally G, Saad RS, et al (2008) Prognostic Significance of Intratumoral and Peritumoral Lymphatic Density and Blood Vessel Density in Invasive Breast Carcinomas. Am J Clin Pathol 129:578–586. https://doi.org/10.1309/2HGNJ1GU57JMBJAQ
17. Wong ALA, Sundar R, Wang TT, et al (2016) Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancer. Oncotarget 7:64089–64099. https://doi.org/10.18632/oncotarget.11596
18. Michaelsen SR, Staberg M, Pedersen H, et al (2018) VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance. Neuro Oncol 20:1462–1474. https://doi.org/10.1093/neuonc/noy103
19. Zhao Y, Adjei AA (2015) Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor. Oncologist 20:660–673. https://doi.org/10.1634/theoncologist.2014-0465
20. Aparicio-Gallego G, Blanco M, Figueroa A, et al (2011) New Insights into Molecular Mechanisms of Sunitinib-Associated Side Effects. Mol Cancer Ther 10:2215–2223. https://doi.org/10.1158/1535-7163.MCT-10-1124
21. Tanaka Y, Shibata MA, Morimoto J, Otsuki Y (2011) Sunitinib suppresses tumor growth and metastases in a highly metastatic mouse mammary cancer model. Anticancer Res 31:1225-34
22. Ang YLE, Ho GF, Soo RA, et al (2020) A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours. BMC Cancer 20:1118. https://doi.org/10.1186/s12885-020-07616-4
23. Wedam SB, Low JA, Yang SX, et al (2006) Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 24:769–777. https://doi.org/10.1200/JCO.2005.03.4645